DSP502

**DSP502** is a novel multifunctional IgG1-Fc-fusion protein developed by KAHR Medical for cancer immunotherapy. Comprising the extracellular domains of TIGIT and PD1, it simultaneously binds PVR (CD155) and PD-L1, overexpressed on cancer and myeloid cells in the tumor microenvironment. By blocking PVR, DSP502 prevents inhibitory signaling through TIGIT and CD96 while promoting DNAM1 costimulatory signaling on T- and NK-cells; its PD1 arm inhibits the PD1/PD-L1 checkpoint to unleash effector T-cells, and the IgG1-Fc delivers immune-activating signals via Fc receptors, resulting in enhanced anti-tumor immunity. Preclinical studies demonstrated increased NK- and PBMC-mediated cytotoxicity, doublet formation between immune and tumor cells, and efficacy in humanized A549-NSCLC xenograft and syngeneic AB12 mesothelioma mouse models, with good tolerability.